Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately.

GoodRx offers a platform for medication savings in the U.S.

The collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those without adequate insurance coverage.

Also Read: GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst

The move also marks the first time Ozempic has been made available to patients at this self-pay price.

In the last year, almost 17 million people came to GoodRx looking for savings and information on GLP-1 medications, a 22% increase from the previous year.

Now, GoodRx is poised to meet this growing demand more effectively.

GoodRx research shows 19 million people lack coverage for any ...